<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364984</url>
  </required_header>
  <id_info>
    <org_study_id>COVID20</org_study_id>
    <nct_id>NCT04364984</nct_id>
  </id_info>
  <brief_title>ARB, ACEi, DRi in COVID-19</brief_title>
  <acronym>BIRCOV</acronym>
  <official_title>ARB, ACEi, DRi Usage in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Practice Prof D. Ivanov</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Practice Prof D. Ivanov</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is supposed to monitor hypertensive patients who are infected or have clinical
      manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be
      considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>BP (hypertensive efficacy)</measure>
    <time_frame>4 weeks</time_frame>
    <description>BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID-19 course</measure>
    <time_frame>3 weeks</time_frame>
    <description>features of disease course: number of patients and duration of fever (above 37.2C), duration of cough (days), duration of throat pain (days), headache (days), nausea or vomiting (days), diarrhea (days), myalgia or arthalgia (days), and numder of patients who need hospital and intensive care unit</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypertension</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ARB group</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received ARBs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEi group</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received ACEis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRi</arm_group_label>
    <description>Hypertensive patients with COVID-19 who received DRis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin converting enzyme inhibitor</intervention_name>
    <description>routine drug intake</description>
    <arm_group_label>ACEi group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with proved COVID-19 and preliminary documented hypertension 1-2 stage on RASi at
        the onset and COVID-19 course during 3 weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive person, stage 1-2

        Exclusion Criteria:

          -  Hypertensive subjects, stage 3, HF (NYHA) 3-4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Practice Prof D.Ivanov</name>
      <address>
        <city>Kiev</city>
        <state>Please Select</state>
        <zip>01014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmytro Ivanov, MD, Prof</last_name>
      <phone>0504448788</phone>
      <phone_ext>+38</phone_ext>
      <email>ivanovdd@i.kiev.ua</email>
    </contact>
    <contact_backup>
      <last_name>Mariia Ivanova, MD, PhD</last_name>
      <phone>0971094024</phone>
      <phone_ext>+38</phone_ext>
      <email>mesangium88@mail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 25, 2020</last_update_submitted>
  <last_update_submitted_qc>April 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACEi, ARB, DRI</keyword>
  <keyword>Clinical features</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

